AndresenV.CamilleriM.BusciglioI.A.GrudellA.BurtonD.McKinzieS. (2007) Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology133: 761–768.
BourasE.P.CamilleriM.BurtonD.D.ThomfordeG.McKinzieS.ZinsmeisterA.R. (2001) Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology120: 354–360.
CamilleriM.KerstensR.RykxA.VandeplasscheL. (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med358: 2344–2354.
6.
CamilleriM.McKinzieS.FoxJ.Foxx-OrensteinA.BurtonD.ThomfordeG. (2004) Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol2: 895–904.
7.
ChiarioniG.WhiteheadW.E.PezzaV.MorelliA.BassottiG. (2006) Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology130: 657–664.
8.
ChitkaraD.K.BredenoordA.J.CremoniniF.Delgado-ArosS.SmootR.L.El-YoussefM. (2004) The role of pelvic floor dysfunction and slow colonic transit in adolescents with refractory constipation. Am J Gastroenterol99: 1579–1584.
9.
CremoniniF.CamilleriM.McKinzieS.CarlsonP.CamilleriC.E.BurtonD. (2005) Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol100: 652–663.
10.
LemboA.CamilleriM. (2003) Chronic constipation. N Engl J Med349: 1360–1368.
11.
LemboA.J.KurtzC.B.MacdougallJ.E.LavinsB.J.CurrieM.G.FitchD.A. (2010) Efficacy of linaclotide for patients with chronic constipation. Gastroenterology138: 886–895.
ManiniM.L.CamilleriM.GoldbergM.SweetserS.McKinzieS.BurtonD. (2010) Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil22: 42–49, e7–8.
14.
ProttG.ShimL.HansenR.KellowJ.MalcolmA. (2010) Relationships between pelvic floor symptoms and function in irritable bowel syndrome. Neurogastroenterol Motil22: 764–769.
15.
QuigleyE.M.VandeplasscheL.KerstensR.AusmaJ. (2009) Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther29: 315–328.
16.
RangnekarA.S.MorganD.KnechtgesP.SaadR.J.FennerD.MorrisA.M. (2008) Complaints suggestive of irritable bowel syndrome are common in patients with puborectalis dyssynergia: An under-recognized overlap syndrome. Gastroenterology134: A423–A423.
17.
RaoS.S.C.TutejaA.K.VellemaT.KempfJ.StessmanM. (2004) Dyssynergic defecation: Demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol38: 680–685.
SurrentiE.RathD.M.PembertonJ.H.CamilleriM. (1995) Audit of constipation in a tertiary referral gastroenterology practice. Am J Gastroenterol90: 1471–1475.
20.
TackJ.van OutryveM.BeyensG.KerstensR.VandeplasscheL. (2009) Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut58: 357–365.
21.
TalleyN.J.FlemingK.C.EvansJ.M.O'KeefeE.A.WeaverA.L.ZinsmeisterA.R. (1996) Constipation in an elderly community: a study of prevalence and potential risk factors. Am J Gastroenterol91: 19–25.
22.
TalleyN.J.ZinsmeisterA.R.Van DykeC.MeltonL.J.3rd (1991) Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology101: 927–934.
23.
TantiphlachivaK.RaoP.AttaluriA.RaoS.S. (2010) Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clin Gastroenterol Hepatol8: 955–960.